Does HIV cause cardiovascular disease?

PLoS Medicine

Volumn 3, Issue 11, 2006, Pages 1986-1987

  Carr, Andrew ^a   Ory, Daniel ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTEGRASE INHIBITOR; LOPINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ABNORMALLY LOW SUBSTRATE CONCENTRATION IN BLOOD; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG ACTIVITY; DRUG EFFECT; GLUCOSE METABOLISM; HEART INFARCTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPID METABOLISM; LIPODYSTROPHY; MORBIDITY; SHORT SURVEY; SIDE EFFECT; BLOOD; REVIEW; VIROLOGY;

ANTI-RETROVIRAL AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; HIV INFECTIONS; HUMANS;

EID: 33845341059     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.0030496     Document Type: Short Survey

References (17)

1. Grinspoon SK, Carr A (2005) Cardiovascular risk and body fat abnormalities in HIV-infected adults. N Engl J Med 352: 48-62.
2. Friis-Møller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, et al. (2003) Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 349: 1993-2003.
3. El-Sadr W, Neaton J (2006) Episodic CD4-guided use of ART is inferior to continuous therapy: Results of the SMART study [abstract]. 13th Conference on Retroviruses and Opportunistic Infections; 5-8 February 2006; Denver, Colorado, United States of America. Available: http://www.retroconference.org/2006/ Abstracts/28085.HTM. Accessed 19 October 2006.
4. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, et al. (1992) Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 74: 1045-1052.
5. Noor MA, Flint OP, Parker RA, Maa J, Witek J, et al. (2005) Evaluation of insulin sensitivity in healthy volunteers treated with low-dose ritonavir combined with atazanavir (ATV/RTV) or lopinavir (LPV/RTV): A prospective, randomised study using hyperinsulinemic, euglycemic clamp and oral glucose tolerance testing [abstract]. 7th International Workshop on Adverse Events and Lipodystrophy in HIV; 13-16 November 2005; Dublin, Ireland.
6. Shafran SD, Mashinter LD, Roberts SE (2005) The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations. HIV Med 6: 421-425.
7. Malan N, Krantz E, David N, Kastango K, Frederick D, et al. (2006) Efficacy and safety of atazanavir-based therapy in antiretroviral naive HIV-1 infected subjects, both with and without ritonavir: 48-week results from AI424-089 [abstract]. 13th Conference on Retroviruses and Opportunistic Infections; 5-8 February 2006; Denver, Colorado, United States of America. Available: http://www.retroconference.org/2006/Abstracts/27965.htm. Accessed 19 October 2006.
8. Johnson MA, Gathe JC Jr, Podzamczer D, Molina JM, Naylor CT, et al. (2006) A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen. J Acquir Immune Defic Syndr 43: 153-160.
9. van der Valk M, Kastelein JJ, Murphy RL, van Leth F, Katlama C, et al. (2001) Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS 15: 2407-2414.
10. Mujawar Z, Rose H, Morrow MP, Pushkarsky T, Dubrovsky L, et al. (2006) Human immunodeficiency virus impairs reverse cholesterol transport from macrophages. PLoS Biol 4: e365. doi:10.1371/journal.pbio.0040365
11. Oram JF, Lawn RM (2001) ABCA1: The gatekeeper for eliminating excess tissue cholesterol. J Lipid Res 42: 1173-1179.
12. Liao Z, Graham DR, Hildreth JE (2003) Lipid rafts and HIV pathogenesis: virion-associated cholesterol is required for fusion and infection of susceptible cells. AIDS Res Hum Retroviruses 19: 675-687.
13. Coppens I, Sinai AP, Joiner KA (2000) Toxoplasma gondii exploits host low-density lipoprotein receptor-mediated endocytosis for cholesterol acquisition. J Cell Biol 149: 167-180.
14. Aiello RJ, Brees D, Bourassa PA, Royer L, Lindsey S, et al. (2002) Increased atherosclerosis in hyperlipidemic mice with inactivation of ABCA1 in macrophages. Arterioscler Thromb Vasc Biol 22: 630-637.
15. Carr A, Emery SE, Law M, Puls R, Lundgren JD, et al. (2003) An objective case definition of lipodystrophy in HIV-infected adults: A case-control study. Lancet 361: 726-735.
16. Garg A (2004) Acquired and inherited lipodystrophies. N Engl J Med 350: 1220-1234.
17. Wang JK, Kiyokawa E, Verdin E, Trono D (2000) The Nef protein of HIV-1 associates with rafts and primes T cells for activation. Proc Natl Acad Sci U S A 97: 394-399.